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Abstract
Asthma management, education and environmental interventions have been
reported as cost-effective in a previous review (Pharm Pract (Granada),
2014;12:493), but methods used to estimate costs and outcomes were not dis-
cussed in detail. This review updates the previous review by providing economic
evidence on the cost-effectiveness of studies identified after 2012, and a detailed
assessment of the methods used in all identified studies. Twelve databases were
searched from 1990 to January 2016, and studies included economic evaluations,
asthma subjects and nonpharmacological interventions written in English. Sixty-four
studies were included. Of these, 15 were found in addition to the earlier review;
53% were rated fair in quality and 47% high. Education and self-management inter-
ventions were the most cost-effective, in line with the earlier review. Self-reporting
was the most common method used to gather resource-use data, accompanied by
bottom-up approaches to estimate costs. Main outcome measures were asthma-
related hospitalizations (69%), quality of life (41%) and utility (38%), with AQLQ and
the EQ-5D being the most common questionnaires measured prospectively at fixed
time points. More rigorous costing methods are needed with a more common qual-
ity of life tool to aid greater replicability and comparability amongst asthma studies.
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1 | INTRODUCTION
Asthma is a chronic lung disease, which affects over 300 million
people worldwide.1 Monitoring asthma through personalized asthma
action plans (PAAPS), taking medication as prescribed, having self-
awareness of potential triggers and attending regular asthma reviews
are some of the ways to manage asthma.2
Much work has explored asthma pharmacological interventions,
and fewer works have considered nonpharmacological.3 It has been
recognized that there needs to be clearer reporting of methods,
outcome measures and all appropriate costs to improve generalizabil-
ity and validity.3,4 Previous reviews have been heavily focused on
clinical interventions and their level of cost-effectiveness.4-7 In order
to ensure appropriate healthcare decisions are made, it is essential
to understand what methodologies underpin these results.
Due to an earlier comprehensive review discussing enhanced
asthma management interventions,3 the objective of this review was
to update and extend this work to include a more critical review
about the methodologies used to estimate costs and outcomes. The
update compares the cost-effectiveness of interventions from post-
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2012 until January 2016, and the extension identifies, describes and
assesses the array of methods used in estimating and evaluating
both costs and outcomes for economic analyses from 1990 to Jan-
uary 2016. The protocol for this review was registered with PROS-
PERO International Prospective Register of Systematic Reviews with
registration number: CRD42016032963.
2 | METHODS
2.1 | Eligibility criteria
2.1.1 | Study design
Original research articles were considered for inclusion. These were
defined as an economic evaluation: cost-effectiveness analysis (CEA),
cost utility analysis (CUA), cost benefit analysis (CBA) or a cost con-
sequences analysis (CCA). Other types of economic studies were
excluded, alongside letters, editorials, magazines, conference
abstracts and reviews.
2.1.2 | Population
Participants with different severities of asthma of any age and from
any country were included.
2.1.3 | Intervention and comparators
Nonpharmacological asthma interventions were included, such as
educational, environmental or self-management interventions. Com-
parators of pharmacological, nonpharmacological or usual care alter-
natives were permitted.
2.1.4 | Outcomes
The primary outcomes were to identify the incremental cost-effec-
tiveness ratios (ICERs) and net benefit results to compare the cost-
effectiveness results in all studies found from the updated search.
The secondary outcomes were to identify the effectiveness and
monetary outcomes (eg, willingness to pay) to explore how they
were evaluated across all included studies.
2.2 | Search strategy
A comprehensive database search was conducted (search terms;
Appendix S1), including databases searched from Yong and Shafie3
and additional databases to ensure all relevant databases were
searched. The included databases searched are as follows: Science-
Direct, Wiley Online Library, EbscoHost, Embase (via OvidSP), Med-
line (via OvidSP) and Scopus, and additional databases: CINAHL (via
EbscoHost), Cochrane (CENTRAL), NHS Economic Evaluation Data-
base (NHS EED), ClinicalTrials.gov, ProQuest and Open Grey. The
latter 3 databases were included to identify any unpublished litera-
ture. Truncation and phrase searching were used for an inclusive
search and to retrieve papers that included the specific quoted
phrases. All databases were restricted to the English language only
with searches from 1990 until January 2016.
2.3 | Study selection
All studies retrieved from the database search were transferred into
EndNote software manager, with duplicates removed. All titles and
abstracts were independently screened for eligibility by 1 reviewer
(CJCB) and then second reviewers (AP, RFSK). Full texts of included
articles were assessed for eligibility, and if any uncertainties arose,
then discussions between 2 reviewers occurred (CJCB, AP or CJCB,
RFSK) with a third reviewer required if there were any discrepancies
(RFSK, AP).
2.4 | Data extraction
Data were extracted from included studies into a predesigned table
(Appendix S2) by 1 independent reviewer (CJCB) with second
reviewers (AP, RFSK) confirming accuracy and discussing any dis-
crepancies.
2.5 | Quality assessment
Two quality assessment checklists were used in this review: Quality
of Health Economic Studies (QHES) (Appendix S3) adapted by Yong
and Shafie,3 but originally designed by Chiou et al,8 and the Philips
et al’s9 criteria for model-based studies. Quality assessment occurred
independently by 1 reviewer (CJCB), with second reviewers (AP,
RFSK) checking for accuracy and resolving any discrepancies through
discussion.
3 | RESULTS
The extensive search retrieved 2118 studies. After duplicates
were removed (287), a further 1715 studies were excluded from
the title and abstract screening. After reviewing the full texts of
the remaining studies, 64 studies were included for analysis (Fig-
ure 1). Of the 64, 15 studies were found in addition to Yong and
Shafie.3
3.1 | Characteristics of the 15 additional papers
Table 1 describes the characteristics of the included studies found in
addition to Yong and Shafie.3
3.1.1 | Study design
There were 5 CEA,10-14 1 CUA,15 4 CBA16-19 and 5 CCA20-24 studies
included. Of these, 7 were randomized control trials,11,14,15,18,21,22,24
3 before and after studies,12,20,23 2 model-based studies,13,17 2
cohort studies16,19 and 1 quasiexperimental study.10
2 | CROSSMAN-BARNES ET AL.
3.1.2 | Population
Population groups chosen were mostly children-focused10-12,16-20,22,23
with 1 adult-only study,21 and combination of the 2.13-15,24 Only 7 stud-
ies12,14,16,18,20,21,23 stated the ethnic background of the populations cho-
sen, with 5 of those representing a mixed ethnic population.16,18,20,21,23
3.1.3 | Interventions
Interventions compared were mainly educational based provided by
school, health professionals or environmental assessors;10-
12,15,16,18,20,21,23 asthma management based using applications and/
or at-risk registers;13,14,19,22,24 and environmental based.17
3.1.4 | Perspective and time horizon
Study cost perspectives included societal,10,15,16,19 governmental,17
health care13-15,24 and individual payer18 with the remaining studies
not stating their perspective.11,12,20-23 Time horizons varied with 1
study having 3 months,10 2 studies having 6 months,14,21 7 studies
having 1 year,11-13,15,20,23,24 3 studies ranging between 2 and
4 years16,18,22 and 1 study having 10 years.17
3.2 | Cost-effectiveness of 15 additional papers
Two studies were dominant (the intervention was less costly and
more effective) compared to the comparator,11,12 and both had
time horizons of 1 year. Two of 5 of the CEA studies were cost-
effective (the ICER was lower than the stated willingness to pay
threshold)10,13 and had varied time horizons (3 months and 1 year,
respectively), perspectives (societal and health care, respectively)
and thresholds. The stated threshold for Atherly et al10 was AUS
$50 000/DALY, whereas Mogasale and Vos13 did not state the
willingness to pay threshold. One of the CEA studies was not
cost-effective.14 The only CUA study15 presented with a cost-
effective ICER and had a time horizon of 1 year based on a
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societal and healthcare perspective separately. Only 1 CBA study16
of 4 CBA studies produced positive net present values for the
adjusted cost savings for years 1, 2 and 3, meaning that the bene-
fits outweighed the costs and the intervention should be imple-
mented. The remaining CCA studies20-24 did not present with an
ICER value and therefore were not compared for cost-effective-
ness; however where available, the cost and outcome results are
detailed in Table 1.
3.3 | Quality assessment for the 15 additional papers
The QHES checklist score varied across the 15 additional studies
found (Table 2). Eight studies scored within the range of fair qual-
ity (50%-74%).10,12,17,19-23 The remaining 7 studies11,13-16,18,24
scored within the range of high quality (>74%). Two studies were
model based, and Fabian et al17 provided a sound quality for the
majority of the assessment categories in the Phillips criteria; how-
ever, a reference to cycle length, internal consistency or method-
ological, structural and heterogeneity uncertainty was not
mentioned. Mogasale and Vos13 also provided a good quality
assessment overall, but were lacking in areas considering cycle
length and uncertainties.
3.4 | Methods used to estimate and value costs
across all 64 papers
Multiple methods were used to gather resource-use data across the
included studies; however, not all studies reported the associated
unit cost for the resource use (Appendix S4). The most commonly
reported items of resource use were asthma-related hospitalizations
(72%) and emergency department visits (70%), with physician visits
(58%), other healthcare professional visits (28%), lost productivity
(38%) and medication use (44%) also collected.
Data were mostly gathered from medical or computerized records
(19%) for hospital-related costs,14,21,24-35 wage rates by employers or
case managers for productivity loss (22%)11,13,15,16,19,26,29,30,33,36-40
and by patient or parent self-reported data (80%) for productivity loss
and quality of life.11,15,21,26,29,30,32,33,41-45 Claims, billing or reim-
bursement data (25%) were often used for those countries who
operate on healthcare insurance systems to also capture hospital-
related costs.15,17,35-37,44,46-50 Costing manuals for health care were
mostly used to gather the unit costs of resources amongst the
papers, such as the Dutch Drug Compendium, 2000, and the Dutch
Manual for Costing in Economic Evaluations51 and the Pharmacy
price listing.20
The methods used to estimate the intervention components’
resource use were not always clearly stated, with all of the necessary
individual components needed to form the successful running of the
intervention and the costing behind this, not often reported. Staff costs,
programme materials and training were the most commonly reported
intervention component costs; however, only some studies stated the
unit costs of the components11,15,29,30,38,39,43,44,49,50,52-56
(Appendix S4). Only a select few papers took into account anyT
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associated travel costs involved in the intervention,29,30,37,38,50,55 and
some studies reimbursed participants for taking part in their
research.10,11,23,35,55 Likewise, with estimating the wider health
resource use, some papers were more detailed with the microcosting of
the intervention component (of which was summed) than others
(Appendix S6 and Appendix S7). The bottom-up approach (individual’s
healthcare service use aggregated) (78%) was generally a more popular
method used to estimate and value the resource-use costs including
most of the intervention component costs, as opposed to the top-down
approach (total healthcare service costs divided by activity days).18-
20,25,31,32,36,41,57-61 Methods used to estimate productivity loss also var-
ied between the human capital approach (each hour lost at work per
patient),30,40,43 the friction cost method (each hour lost at work until the
employer replaces the patient who is unable to work)15,33 or using the
caregivers income multiplied by the mid-point of the family’s income.11
3.5 | Methods used to estimate and value
outcomes (1990 to January 2012)
The outcomes measured varied widely, across all included studies,
with multiple data collection methods often used within each study
(Appendix S5). The hospital visits and emergency department visits
were the most frequently stated resource use, and they were also
the most common type of outcomes measured. Over two-thirds
identified the emergency department visits or hospitalizations (46
papers or 45 papers, respectively), followed by approximately one-
third investigating quality of life and physician (GP) visits (26 papers
and 29 papers, respectively). Other papers reported a wide range of
other outcomes, including intensive care admissions,23,28,32,58 fre-
quency of exacerbations and symptoms,11,14,22,62,63 asthma knowl-
edge,10,39,48,60 peak expiratory flow (PEF),30,38,42,48,54,58,63-67 forced
expiratory volume,15,26,30,31,37,42,43,54,58,64-66 forced vital capacity
(FVC)15,30,31,37,42,54,58,64-66 and medications.18,30,39,47,50,58,68,69 A PEF
meter was used to estimate the PEF, a spirometry was used to esti-
mate the forced expiratory volume in one second and FVC, and his-
tamine was used to estimate airway responsiveness.
A wide selection of health questionnaires were used to collect
data in the studies (Figure 2), mostly by patient self-report, but often
in conjunction with face-to-face visits12,14,37,39,40,51,58,64-66,70 or tele-
phone interview sessions.11,13,18,25,36,44,50,53,57,60,62,69-71 Other
options of completing questionnaire data were by proxy, that is, par-
ent-reported questionnaires,12,42,55,70 caregivers’ questionnaires40 or
case managers’ self-reported questionnaires.16,56
The disease-specific questionnaires—Asthma Quality of Life Ques-
tionnaire (AQLQ)15,21,34,43,48,58 and the St. George’s Respiratory Ques-
tionnaire (SGRQ)31,37,64-66—and the generic questionnaires—
EuroQol-5 Dimensions (EQ-5D)15,29,33,42 and 15 Dimensions
(15D)64-67—were the most commonly used. The studies that used
the EQ-5D and Short Form-6 Dimension (SF-6D)15 converted the
scores into utility values and used these to estimate quality-adjusted
life years (QALYs). Other studies that did not estimate QALYs used
total and/or overall mean scores from the health questionnaires in
their analysis.
4 | DISCUSSION
This systematic review updated and extended a previous study that
evaluated the cost-effectiveness of nonpharmacological asthma inter-
ventions with databases searched from 1990 until 2012.3 The extension
included extending this database search until January 2016, and the
update included an assessment of the methods used to estimate both
costs and outcomes in all studies found from 1990 until 2016.
4.1 | Main findings
In line with the findings from Yong and Shafie,3 the additional
education and self-management study-based interventions found
in this review were deemed most cost-effective or dominant. The
quality of studies has since improved with the additional studies
presenting with fair (50%-74%) to high (>74%) quality. Multiple
methods were often used to gather resource-use data with self-
report being the most common, the bottom-up approach being
the most common estimation method of resource use gathered,
and health-related questionnaires being a common outcome mea-
sure with AQLQ and EQ-5D being the most common HRQOL
questionnaires.
4.2 | Comparison with other studies
Earlier systematic reviews of asthma interventions also highlighted
the importance of the quality assessment in studies.5,6,72,73 One
study, in particular, believed their peak flow monitoring intervention
was cost-effective, but could not conclude this due to the study
qualities being so low.72 This review shows that the quality of stud-
ies has much improved since then, with nearly 50% of the studies
found post-2012 presenting with high quality.
Although improvement has been noticed in the quality of the
studies, some still have an inadequate follow-up, which can reduce
validity and generalizability.74 It was previously acknowledged that a
short time horizon was inadequate for chronic conditions,6 with a
time horizon of 3 months or less considered to be unacceptable.4
The additional studies found in this review presented with 1 study
having a time horizon of 3 months,10 and others longer at between
6 months and 10 years.
As different cost perspectives are used amongst the included
studies in this review, it becomes difficult to compare the total costs
associated with each intervention. An earlier review noted that the
author’s definitions of direct medical costs, direct nonmedical costs
and indirect costs sometimes varied, where costs assigned to direct
nonmedical costs should have been assigned to indirect costs.72 Pre-
vious literature discusses that a societal perspective is important to
synthesize the evidence and gain a proper understanding on peak
flow monitoring interventions.72,75,76 However, perspectives chosen
can differ from country to country and the definitions of a societal
perspective can also vary.
It was surprising that only about a quarter of papers included
lost productivity as an outcome measure. Due to asthma being a
8 | CROSSMAN-BARNES ET AL.
T
A
B
L
E
2
Q
ua
lit
y
as
se
ss
m
en
t
sc
o
re
s
u
si
ng
Q
H
E
S
ch
ec
kl
is
t
fo
r
th
e
1
5
ad
di
ti
o
na
l
st
ud
ie
s
Q
H
E
S
cr
it
er
ia
no
.a
A
th
er
ly
et
al
(2
0
0
9
)1
0
B
ha
um
ik
et
al
(2
0
1
3
)1
6
C
as
tr
o
et
al
(2
0
0
3
)2
1
Fa
bi
an
et
al
(2
0
1
4
)1
7
F
lo
re
s
et
al
(2
0
0
9
)1
1
H
ig
gi
ns
et
al
(1
9
9
8
)2
0
K
ar
ni
ck
et
al
(2
0
0
7
)1
8
La
ra
et
al
(2
0
1
3
)1
2
M
cC
o
w
an
et
al
(1
9
9
7
)2
2
M
o
ga
sa
le
et
al
(2
0
1
3
)1
3
R
ya
n
et
al
(2
0
1
2
)1
4
Sm
it
h
et
al
(2
0
1
2
)2
4
T
ai
et
al
(2
0
1
1
)1
9
T
ur
co
tt
e
et
al
(2
0
1
4
)2
3
W
ill
em
s
et
al
(2
0
0
7
)1
5
1
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
2
2
4
0
4
0
0
4
0
0
2
2
2
2
0
2
3
8
6
8
4
8
6
8
6
8
8
8
8
6
6
8
4
0
0
0
1
0
0
1
0
0
0
0
0
0
0
1
5
4
.5
4
.5
4
.5
4
.5
4
.5
4
.5
4
.5
4
.5
0
9
9
4
.5
0
4
.5
9
6
6
6
0
0
6
0
0
0
0
6
0
6
0
0
6
7
5
5
5
0
5
5
5
5
0
5
5
5
5
5
5
8
7
7
0
5
7
7
7
7
0
0
7
7
0
7
7
9
6
6
2
6
8
8
8
6
8
8
6
6
8
8
8
1
0
6
6
4
0
6
4
4
6
4
0
4
6
0
4
4
1
1
0
7
7
0
7
7
7
7
7
7
0
7
0
7
7
1
2
4
8
8
4
.5
4
8
8
5
2
8
8
8
2
4
8
1
3
3
.5
7
3
.5
7
3
.5
3
.5
3
.5
3
.5
3
.5
7
7
7
7
7
3
.5
1
4
0
6
6
0
0
6
6
3
0
0
3
0
6
0
6
1
5
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
1
6
0
3
3
3
3
0
3
3
3
3
3
3
0
3
0
T
o
ta
l
6
7
9
0
.5
6
6
5
4
7
7
7
4
8
4
7
1
5
0
.5
7
8
7
7
8
4
.5
5
1
7
0
.5
8
9
.5
a F
ul
l
ta
bl
e
o
f
cr
it
er
ia
an
d
sc
o
ri
ng
sy
st
em
ca
n
be
fo
un
d
in
A
pp
en
di
x
S3
.
CROSSMAN-BARNES ET AL. | 9
chronic condition, it is thought that more papers would have dis-
cussed lost productivity, and the possible implications that this may
have on presenteeism and/or absenteeism. With patients who have
asthma exacerbations often not well enough to continue at work or
with their usual activities, it is important to include nonmedical
resource use and productivity costs in studies.77
In all of the included studies in this review, the intervention
details were often reported, but the details surrounding the costs of
conducting the interventions with the associated unit costs were lim-
ited. Three studies provided comprehensive details about how they
estimated the intervention, including the breakdown of the interven-
tion components, their associated unit costs and the methods chosen
to estimate such costs.15,29,55 The common approach between all 3
was a microcosting approach. Difficulties can sometimes occur with
this approach when prices for certain resources are not always avail-
able from various data sources, leaving room for customization.78
0 1 2 3 4 5 6 7
Children's health survery for asthma
Panic-fear personality scale
Respiratory Illness opinion survey
Modiﬁed Marks Asthma Quality of Life (MAQLQ-M)
Asthma Outcome Monitoring System quesonnaire (AOMS)
Funconal Severity of Asthma Scale (FSAS)
Parent asthma management self eﬃcacy scale
Short Form 6 Dimensions (SF6D)
Pediatric asthma quality of life scales (PQLQ)
Pediatric Illness-Related Competence scale (PIRC)
Assessment of Quality of Life Instrument
Knowledge, atude & self-eﬃcacy asthma quesonnaire (KASE-AQ)
Mini-asthma quality of life quesonnaire
Borg Dyspnea Score & Severity of asthma symptoms
Paent sasfacon survey (PS)
Asthma episode self-management simulaon (AESM)
KINDL quesonnaire
Short Form 36 Quesonnaire (SF36)
Pediatric quality of life inventory (PedsQL)
Pediatric asthma caregiver's quality of life
Pediatric asthma quality of life quesonnaire (PAQLQ)
Asthma Control Quesonnaire (ACQ)
Self Eﬃcacy Scale (SES)
EuroQol 5 Dimensions (EQ-5D)
15 Dimensions quesonnaire
St. George's respiratory quesonnaire (SGRQ)
Asthma Quality of Life Quesonnaire (AQLQ)
No. of studies
He
al
th
 q
ue
s
on
na
ire
s 
F IGURE 2 Different health questionnaires used in studies
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From the 26 studies that also incorporated quality of life as an
outcome measure, there were over 20 different questionnaires that
were used to measure this. Many of the questionnaires used to anal-
yse quality of life were more specific to asthma, but there did not
appear to be a preferred measure that was used across the studies.
The EQ-5D-3L questionnaire (5 dimensions with 3 levels: no prob-
lems, moderate problems and extreme problems) was used across a
number of studies, but often used alone and not in conjunction with
another quality of life questionnaire. As discussed by Yong and Sha-
fie,3 EQ-5D-3L might not be the best tool to use for quality of life
in asthma, as it is not seen as sensitive enough to detect differences
in HRQOL particularly in people with mild asthma. However, there
have been recent developments of a new EQ-5D-5L questionnaire,
which includes the same 5 dimensions but with 5 levels: no problems,
slight problems, moderate problems, severe problems or extreme
problems.79 The newly developed EQ-5D-5L tool may be more suit-
able as it was designed to be more sensitive and reduce the high ceil-
ing effects. This has been confirmed in several studies that have
shown increased reliabilities, sensitivities and validities.79,80
4.3 | Recommendations for future
In the light of the above, there are many areas for which focus is
required when conducting an asthma study. The main recommenda-
tions are to use time horizons greater than 3 months to ensure ade-
quate follow-up, to include all relevant costs and benefits that have
been accounted for as asthma is a chronic condition (particularly the
high cost drivers77), and to conduct a microcosting approach where
possible. For economic evaluations where QALYs are estimated, the
EQ-5D-5L can be used as a generic measure. However, even though
this has been proven in earlier studies to show positive results in
terms of increased sensitivities and validities compared to the EQ-
5D-3L, due to it being a relatively new questionnaire, it may be
advisable to use this in conjunction with a more established disease-
specific questionnaire. Due to the difficulties that arise in economic
evaluations and to ensure the comparability across different coun-
tries and decision-makers,81 it may be useful to adhere to an inter-
national reference case, which is a useful guide from the planning
stages of research through to reporting findings and completion.
Future research should also ensure that the appropriate guidelines
and checklists are adhered to, such as the TiDieR checklist,82 the
CHEERS statement,83 CONSORT statement84 and the COMET initia-
tive85 for ease of replicability of both the intervention and control
groups by clinicians or researchers looking to implement or expand
research ideas, respectively. This will in turn aid the comparability of
studies.
4.4 | Strengths and limitations
The strength of this review is that it provides a comprehensive syn-
thesis of studies from an extensive database search with studies
analysed from 12 databases. The included studies help to understand
how asthma interventions and methodologies chosen have evolved
over the years, with discussions leading to recommendations for
future practice. Bias has been reduced during this review by includ-
ing 2 independent reviewers during the systematic review process.
However, a limitation of this review is that only English language
studies were included, with restrictions of this placed during the
database search. Therefore, we are unable to acknowledge how
many non-English studies have been excluded from this review, but
it is apparent that due to this selection bias, additional studies may
have been relevant for inclusion in this review.
5 | CONCLUSIONS
The additional 15 studies identified were of fair to high quality. Most
of the additional studies found had dominant or cost-effective inter-
ventions that were educational or management based, which mir-
rored the previous review. The methods used to estimate costs and
outcomes varied, with the bottom-up approach being the most com-
mon approach; however, the reporting of unit costs was lacking
amongst some studies, with only a few studies providing detailed
microcosting methodologies for the intervention components. For
future studies, a thorough description of methods used in all compo-
nents of the study is needed, including reporting of unit costs and a
common quality of life measure to provide more comparability.
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